Reducing Nephropathy with Inhibitors of Soluble Epoxide Hydrolase and Epoxyeicosanoids

a technology of epoxyeicosanoids and soluble epoxide hydrolase, which is applied in the direction of drug compositions, peptide/protein ingredients, metabolic disorders, etc., can solve the problems of nephropathy and kidney failure, kidney damage tends to increase hypertension, and cannot explain nephropathy, so as to inhibit the progression of nephropathy and reduce blood pressure in a person.

Inactive Publication Date: 2009-01-15
RGT UNIV OF CALIFORNIA
View PDF11 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Nephropathy and kidney failure can result even when diabetes is controlled with drugs and exercise.
Hypertension is considered a significant factor in the development of nephropathy, and kidney damage tends to increase hypertension.
Hypertension alone, however, cannot explain nephropathy due to diabetes, since bringing blood pressure down to normal levels will slow development of nephropathy, but will not block it.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Reducing Nephropathy with Inhibitors of Soluble Epoxide Hydrolase and Epoxyeicosanoids

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0104]Urinary protein is usually a combination of albumin, globulins and minor components. Increased proteinuria (albuminuria) is associated with progressive kidney disease. The concentration of different urinary biomarkers responds to therapeutically relevant agents. Thus, the regular measurement of urinary albumin is a useful guide to the success of therapy in patients with many chronic renal diseases. Measurement of urinary albumin is often used in conjunction with measurements of other proteins and metabolic products, including serum and urine urea, creatinine, and ion concentrations, as well as serum C reactive protein, macroglobulin and various cytokines, in monitoring the progression of kidney damage.

[0105]The obese Zucker rat (OZR) is well known to rapidly develop numerous clinically relevant pathological conditions including, in addition to type 2 diabetes, hypertension and obesity, and spontaneous renal failure. E.g., Schmitz, P. G. et al., Sem. Nephr. 9(4), 354-369 (1989)...

example 2

[0107]This Example provide exemplar assays for screening potential sEH inhibitors using affinity purified recombinant human, mouse and rat enzyme preparations.

[0108]Potential sEH inhibitors can be screened by high throughput bioassay methods incorporating recombinant mouse and human sEHs. To evaluate the relative potency of the inhibitors, IC50 values are examined. The IC50 is the concentration of inhibitor that reduces enzyme activity by 50%, and is typically determined by regression of at least five datum points with a minimum of two points in the linear region of the curve on either side of the IC50. Conveniently, the curve is generated from several separate runs, each in triplicate, to obtain the standard deviation.

[0109]Enzyme Preparation: Recombinant rat, mouse, pig, and human sEHs can be produced in a baculovirus expression system and purified by affinity chromatography, as taught in Grant et al., J Biol Chem, 268(23):17628-17633 (1993); Beetham et al., Arch. Biochem. Biophys...

example 3

[0112]This Example sets forth exemplar assays for testing the ability of sEH inhibitors, or a combination of sEH inhibitors and EETs, to delay the onset of nephropathy in an animal model of diabetes.

[0113]Using analysis of blood and urine biomarkers determine if the onset of renal damage is delayed.

[0114]Obese Zucker rats (“OZR”) are an autosomally recessive genetic model of obesity that is a commonly used model of relatively early onset human obesity. E.g., Farkas and Schlenker, Am. J. Respir. Crit. Care Med., 150(2):356-362 (1994). OZR are treated for 10 weeks with a known or potential sEH inhibitor (the “test agent”). To verify that effective levels of the test agent are maintained, the concentration of the test agent and indicator metabolites in blood and urine are monitored by LC-MS. Blood and urine samples are obtained once a week. Optionally, the kidneys are monitored in situ with high resolution ultrasound. Unlike mice, rats respond to vascular inflammation with high levels ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
pHaaaaaaaaaa
pHaaaaaaaaaa
sizeaaaaaaaaaa
Login to view more

Abstract

The invention provides uses and methods for reducing nephropathy in persons with diabetes mellitus (particularly Type 2 diabetes), in persons with metabolic syndrome, in persons with triglyceride levels over 215 mg / dL, and in persons with a cholesterol level over 200 mg / dL, by administering an inhibitor of soluble epoxide hydrolase (“sEH”). Optionally, a cis-epoxyeicosantrienoic acid (“EET”) can be administered with the sEH inhibitor. The invention further provides for using EETs in conjunction with one or more sEH inhibitors to reduce hypertension, and for compositions of EETs coated with a material insoluble in an acid of pH 3 but soluble in a solution with a pH of 7.4 or higher.

Description

CROSS-REFERENCES TO RELATED APPLICATIONS[0001]This application claims the benefit of U.S. Provisional Application No. 60 / 553,847, filed Mar. 16, 2004, the contents of which are hereby incorporated by reference.STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT[0002]This invention was made with Government support under Grant Nos. DK35747 and ES02710 awarded by the National Institutes of Health. The Government has certain rights in this invention.REFERENCE TO A “SEQUENCE LISTING,” A TABLE, OR A COMPUTER PROGRAM LISTING APPENDIX SUBMITTED ON A COMPACT DISK[0003]Not applicableBACKGROUND OF THE INVENTION[0004]In 2003, the International Diabetes Federation estimated that there were 194 million people worldwide with diabetes. Of these, some 16 million were estimated to be in the United States. Many diabetes sufferers undergo a slow deterioration of the kidneys, a process known as nephropathy. The end stage of nephropathy is kidney failure, or end s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/7105A61K31/196A61K31/215A61P3/10A61P9/12A61K31/17
CPCA61K31/17A61K31/70A61K31/355A61P13/12A61P25/00A61P3/00A61P3/04A61P3/06A61P43/00A61P9/12A61P3/10
Inventor HAMMOCK, BRUCE DWATANABE, TAKAHOMA, SEUNG JINBENNETT, SUSAN E.STERN, JUDITH S.MORISSEAU, CHRISTOPHEKIM, IN-HAE
Owner RGT UNIV OF CALIFORNIA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap